SAWAI GROUP HOLDINGS Co., Ltd. (JP:4887)
:4887
Want to see JP:4887 full AI Analyst Report?
4887 Stock Chart & Stats
¥2359.00
-¥48.50(-2.23%)
At close: 4:00 PM EST
¥2359.00
-¥48.50(-2.23%)
Day’s Range― - ―
52-Week Range¥1,689.50 - ¥2,447.00
Previous CloseN/A
Volume473.80K
Average Volume (3M)299.27K
Market Cap
¥207.15B
Enterprise Value¥318.37B
Total Cash (Recent Filing)¥46.12B
Total Debt (Recent Filing)¥122.49B
Price to Earnings (P/E)13.9
Beta0.42
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.28%
Share Statistics
EPS (TTM)-91.57
Shares Outstanding115,487,140
10 Day Avg. Volume288,420
30 Day Avg. Volume299,266
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.41
Price to Sales (P/S)1.30
P/FCF Ratio33.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,741.67Price Target Upside16.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)172.51
Revenue Forecast (FY)¥218.50B
Bulls Say, Bears Say
Bulls Say
Top-line MomentumSawai has delivered robust top-line momentum with TTM revenue up 34%, indicating strong demand for its generics portfolio and successful product launches. Durable revenue expansion supports scale economies in manufacturing and a larger base for steady future sales over the next 2–6 months.
Operating Cash GenerationThe group generates meaningful operating cash (¥20.3B TTM) and positive free cash flow (¥5.8B TTM), providing internal funding for working-capital needs, capex and dividends. Persistent positive cash generation, even if uneven, underpins financial flexibility and investment capacity.
Balance-sheet SubstanceSubstantial equity relative to assets (¥178.8B of equity on ¥377.0B assets) signals a solid capital base. This supports resilience to operational shocks, underpins credit lines and investment in manufacturing capacity—important for a generics-focused pharma business over the medium term.
Bears Say
Margin CompressionNet margin has compressed materially from ~12.1% to ~4.9% TTM, reflecting cost pressure or pricing erosion in generics. Sustained margin weakness reduces earnings quality and limits reinvestment capacity, making profitability more sensitive to input-cost swings and competitive pricing dynamics.
Rising LeverageLeverage increased meaningfully (debt/equity ~0.60 vs ~0.41 prior), raising fixed-charge obligations and reducing financial flexibility. Higher reliance on debt constrains strategic optionality—less room for opportunistic M&A or cushioning against revenue shocks in a low-margin generics environment.
Volatile Free Cash FlowFree cash flow is positive but volatile and declined TTM (-8.74%), with prior-year negatives. Cash conversion (~34% of net income) is moderate, limiting reliable internal funding for growth or payouts. Persistent FCF variability heightens funding and execution risk for medium-term plans.
SAWAI GROUP HOLDINGS Co., Ltd. News
4887 FAQ
What was SAWAI GROUP HOLDINGS Co., Ltd.’s price range in the past 12 months?
SAWAI GROUP HOLDINGS Co., Ltd. lowest stock price was ¥1689.50 and its highest was ¥2447.00 in the past 12 months.
What is SAWAI GROUP HOLDINGS Co., Ltd.’s market cap?
SAWAI GROUP HOLDINGS Co., Ltd.’s market cap is ¥207.15B.
When is SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date?
SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 89 days.
How were SAWAI GROUP HOLDINGS Co., Ltd.’s earnings last quarter?
SAWAI GROUP HOLDINGS Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥2.7 earnings per share for the quarter, missing the consensus estimate of ¥27.897 by -¥30.597.
Is SAWAI GROUP HOLDINGS Co., Ltd. overvalued?
According to Wall Street analysts SAWAI GROUP HOLDINGS Co., Ltd.’s price is currently Undervalued.
Does SAWAI GROUP HOLDINGS Co., Ltd. pay dividends?
SAWAI GROUP HOLDINGS Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.28%. See more information on SAWAI GROUP HOLDINGS Co., Ltd. dividends here
What is SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate?
SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAWAI GROUP HOLDINGS Co., Ltd. have?
SAWAI GROUP HOLDINGS Co., Ltd. has 115,487,140 shares outstanding.
What happened to SAWAI GROUP HOLDINGS Co., Ltd.’s price movement after its last earnings report?
SAWAI GROUP HOLDINGS Co., Ltd. reported an EPS of -¥2.7 in its last earnings report, missing expectations of ¥27.897. Following the earnings report the stock price went down -4.582%.
Which hedge fund is a major shareholder of SAWAI GROUP HOLDINGS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4887
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
4887 Stock 12 Month Forecast
Average Price Target
¥2,741.67
▲(16.22% Upside)
Technical Analysis
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---